RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Sonnet Biotherapeutics Holdings Stock

Sonnet Biotherapeutics Holdings P/S 2024

Sonnet Biotherapeutics Holdings P/S

44.24

Ticker

SONN

ISIN

US83548R1059

WKN

A2P2NP

As of Sep 10, 2024, Sonnet Biotherapeutics Holdings's P/S ratio stood at 44.24, a -40.97% change from the 74.94 P/S ratio recorded in the previous year.

The Sonnet Biotherapeutics Holdings P/S history

Sonnet Biotherapeutics Holdings Aktienanalyse

What does Sonnet Biotherapeutics Holdings do?

Sonnet Biotherapeutics Holdings Inc is a biopharmaceutical company specializing in the development of innovative cancer immunotherapies. It was founded in 2011 by Dr. Pankaj Mohan and is headquartered in Princeton, New Jersey. Sonnet's business model is based on the development of therapies that are based on the company's proprietary Sonnet Protein Design System platform. This system enables researchers to design customized proteins that can selectively recognize and target tumor cells, allowing for targeted precision oncology therapy and minimizing unwanted side effects. Sonnet's team focuses on research and development of cancer immunotherapies in various areas including triple-negative breast cancer, prostate cancer, glioblastoma, and mesothelioma. The company also collaborates closely with leading academic institutions and research facilities to leverage the latest insights and technologies in cancer research. An important aspect of Sonnet's business is the collaboration with other companies for product and therapy development. The company has partnerships with some of the leading names in the biopharmaceutical industry such as Cancer Research UK, Lonza Group, and BioNTech. Through such collaborations, they aim to develop drug candidates and therapies that address medical needs and offer new treatment options. Sonnet's products include early-stage approaches such as SL-101, an immunotherapy for the treatment of mesothelioma that aims to reduce tumor mass and increase survival rates. SL-279/SL-037 is a cancer therapeutic currently in preclinical development, focusing on the Homolog Recombinant Assay. It aims to inhibit Tumor Calix 2, a potential target found in many different types of tumors. Sonnet is still in an early stage of development and has not yet launched any products on the market, but the company has a promising pipeline of various products and collaborations with major partners and leading researchers. The company is also taking measures to market its innovative platform and products across geographical borders. Overall, Sonnet has the potential to have a significant impact on cancer treatment and lead oncology therapy into a new era. Collaboration with other companies and leading research organizations will contribute to the development of innovative products and therapies. Ongoing research and development in the field of biotherapeutic cancer treatment at Sonnet offer hope for breakthrough products that could help patients worldwide and change the lives of those living with cancer. Sonnet Biotherapeutics Holdings ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding Sonnet Biotherapeutics Holdings's P/S Ratio

Sonnet Biotherapeutics Holdings's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Sonnet Biotherapeutics Holdings's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Sonnet Biotherapeutics Holdings's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Sonnet Biotherapeutics Holdings’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Sonnet Biotherapeutics Holdings stock

What is the price-to-earnings ratio of Sonnet Biotherapeutics Holdings?

The price-earnings ratio of Sonnet Biotherapeutics Holdings is currently 44.24.

How has the price-earnings ratio of Sonnet Biotherapeutics Holdings changed compared to last year?

The price-to-earnings ratio of Sonnet Biotherapeutics Holdings has increased by -40.97% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Sonnet Biotherapeutics Holdings high compared to other companies?

Yes, the price-to-earnings ratio of Sonnet Biotherapeutics Holdings is high compared to other companies.

How does an increase in the price-earnings ratio of Sonnet Biotherapeutics Holdings affect the company?

An increase in the price-earnings ratio of Sonnet Biotherapeutics Holdings would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Sonnet Biotherapeutics Holdings affect the company?

A decrease in the price-earnings ratio of Sonnet Biotherapeutics Holdings would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Sonnet Biotherapeutics Holdings?

Some factors that influence the price-earnings ratio of Sonnet Biotherapeutics Holdings are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Sonnet Biotherapeutics Holdings pay?

Over the past 12 months, Sonnet Biotherapeutics Holdings paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Sonnet Biotherapeutics Holdings is expected to pay a dividend of 0 USD.

What is the dividend yield of Sonnet Biotherapeutics Holdings?

The current dividend yield of Sonnet Biotherapeutics Holdings is .

When does Sonnet Biotherapeutics Holdings pay dividends?

Sonnet Biotherapeutics Holdings pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Sonnet Biotherapeutics Holdings?

Sonnet Biotherapeutics Holdings paid dividends every year for the past 0 years.

What is the dividend of Sonnet Biotherapeutics Holdings?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Sonnet Biotherapeutics Holdings located?

Sonnet Biotherapeutics Holdings is assigned to the 'Health' sector.

Wann musste ich die Aktien von Sonnet Biotherapeutics Holdings kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Sonnet Biotherapeutics Holdings from 9/10/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/10/2024.

When did Sonnet Biotherapeutics Holdings pay the last dividend?

The last dividend was paid out on 9/10/2024.

What was the dividend of Sonnet Biotherapeutics Holdings in the year 2023?

In the year 2023, Sonnet Biotherapeutics Holdings distributed 0 USD as dividends.

In which currency does Sonnet Biotherapeutics Holdings pay out the dividend?

The dividends of Sonnet Biotherapeutics Holdings are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Sonnet Biotherapeutics Holdings

Our stock analysis for Sonnet Biotherapeutics Holdings Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Sonnet Biotherapeutics Holdings Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.